TX
TherapeuticsMD, Inc.
TXMD · NASDAQ
$2.19 +0.23% (+$0.01)
1M +6.31%
Market Cap $25.2M
P/E Ratio -
Div. Yield -
ROE 0.80%
Piotroski F-Score Moderate
4/9Valuation
80 /100
Cheap P/FCF 8.09x
P/S 7.72x
P/B 0.93x
Growth
0 /100
Declining Book val. growth 8.55%
Rev. growth 64.91%
FCF growth N/A
Profitability
50 /100
Moderate Op. margin 118.20%
Gross margin 100.00%
FCF margin 95.41%
Quality
2 /100
Poor ROA 0.58%
ROIC 12.92%
Asset turnover 0.09x
Debt
69 /100
Low Int. coverage -1,405.25x
Debt/Equity 0.20x
Current ratio 3.22x
Stability
56 /100
Moderate EPS volatility 10.76%
Beta 0.65x
Profitable years 0
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o TXMD
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Marlan D. Walker
Employees
1
Headquarters
Boca Raton
Nadchodzące wydarzenia
17 LIS
Earnings
Upcoming earnings report